Abstract: PurposeA joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform calculations and comparisons with model-based dose calculation algorithms (MBDCAs). Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No. 186 (TG-186) for MBDCAs. To do so, in this work a hypothetical, generic high-dose rate (HDR) Ir-192 shielded applicator has been designed and benchmarked. MethodsA generic HDR Ir-192 shielded applicator was designed based on three commercially available gynecological applicators as well as a virtual cubic water phantom that can be imported into any DICOM-RT compatible treatment planning system (TPS). The absorbed dose distribution around the applicator with the TG-186 Ir-192 source located at one dwell position at its center was computed using two commercial TPSs incorporating MBDCAs (Oncentra((R)) Brachy with Advanced Collapsed-cone Engine, ACE, and BrachyVision ACUROS) and state-of-the-art Monte Carlo (MC) codes, including ALGEBRA, BrachyDose, egs_brachy, Geant4, MCNP6, and Penelope2008. TPS-based volumetric dose distributions for the previously reported source centered in water and source displaced test cases, and the new source centered in applicator test case, were analyzed here using the MCNP6 dose distribution as a reference. Volumetric dose comparisons of TPS results against results for the other MC codes were also performed. Distributions of local and global dose difference ratios are reported. ResultsThe local dose differences among MC codes are comparable to the statistical uncertainties of the reference datasets for the source centered in water and source displaced test cases and for the clinically relevant part of the unshielded volume in the source centered in applicator case. Larger local differences appear in the shielded volume or at large distances. Considering clinically relevant regions, global dose differences are smaller than the local ones. The most disadvantageous case for the MBDCAs is the one including the shielded applicator. In this case, ACUROS agrees with MC within [-4.2%, +4.2%] for the majority of voxels (95%) while presenting dose differences within [-0.12%, +0.12%] of the dose at a clinically relevant reference point. For ACE, 95% of the total volume presents differences with respect to MC in the range [-1.7%, +0.4%] of the dose at the reference point. ConclusionsThe combination of the generic source and generic shielded applicator, together with the previously developed test cases and reference datasets (available in the Brachytherapy Source Registry), lay a solid foundation in supporting uniform commissioning procedures and direct comparisons among treatment planning systems for HDR Ir-192 brachytherapy.

Abstract: A low-noise head amplifier has been developed for the extra low energy antiproton ring beam trajectory, orbit, and intensity measurement system at CERN. This system is based on 24 double-electrode electrostatic beam position monitors installed around the ring. A head amplifier is placed close to each beam position monitor to amplify the electrode signals and generate a difference and a sum signal. These signals are sent to the digital acquisition system, about 50 m away from the ring, where they are digitized and further processed. The beam position can be measured by dividing the difference signal by the sum signal while the sum signal gives information relative to the beam intensity. The head amplifier consists of two discrete charge preamplifiers with junction field effect transistor (JFET) inputs, a sum and a difference stage, and two cable drivers. Special attention has been paid to the amplifier printed circuit board design to minimize the parasitic capacitances and inductances at the charge amplifier stages to meet the gain and noise requirements. The measurements carried out on the head amplifier showed a gain of 40.5 and 46.5 dB for the sum and difference outputs with a bandwidth from 200 Hz to 75 MHz and an input voltage noise density lower than 400 pV/v Hz. Twenty head amplifiers have been already installed in the ring and they have been used to detect the first beam signals during the first commissioning stage in November 2016.

Abstract: The difference between the CP asymmetries in the decays Lambda(+)(C) -> pK(-)K(+) and Lambda(+)(C) -> p pi(-)pi(+) is presented. Proton-proton collision data taken at centre-of-mass energies of 7 and 8 TeV collected by the LHCb detector in 2011 and 2012 are used, corresponding to an integrated luminosity of 3 fb(-1). The Lambda(+)(C) candidates are reconstructed as part of the Lambda(0)(b) -> Lambda(+)(c)mu X- decay chain. In order to maximize the cancellation of production and detection asymmetries in the difference, the final-state kinematic distributions of the two samples are aligned by applying phase-space-dependent weights to the Lambda(+)(C) -> pK(-)K(+) sample. This alters the definition of the integrated CP asymmetry to A(CP)(wgt)(p pi(-)pi(+)). Both samples are corrected for reconstruction and selection efficiencies across the five-dimensional Lambda(+)(C) decay phase space. The difference in CP asymmetries is found to be Delta A(CP)(wgt) = A(CP)(pK(-)K(+)) – A(CP)(wgt)(p pi(-)pi(+)) = (0.30 +/- 0.91 +/- 0.61) %, where the first uncertainty is statistical and the second is systematic.